Blog | HemaCare

A new study shows that we may be able to boost the grafting ability in cells for people receiving a bone marrow transplant.

Allogenic stem cell transplantation is a treatment approach in people with diseases that are destructive to the bone marrow, such as multiple myeloma, leukemia, and Hodgkin´s lymphoma. The goal is to restore bone marrow after total-body chemotherapy and irradiation. The transplantation procedure involves transferring hematopoietic stem cells from compatible, healthy donors to a patient. An important complication of this procedure is rejection and destruction of the donated stem cells by the recipient’s immune system before engraftment can occur.

While no cure exists for ALS, researchers are finding ways to use unmodified human bone marrow CD34+ cells for spinal restoration.

The renowned physicist Stephen Hawking influenced how countless scientists worldwide view the universe. He also demonstrated his remarkable ability to survive amyotrophic lateral sclerosis (ALS) for 55 years. He is thought to be the longest survivor of ALS. According to the ALS Association, 50% of those with ALS survive for about 3 years after diagnosis, 20% survive for 5 or more years, and 10% survive for 10 years or more. There is no cure for ALS, and therapies that can slow or delay progression, decrease symptoms, and repair damaged spinal-cord tissue are continuously sought.

The leading cause of death for U.S. citizens is cardiovascular disease, which affects nearly a third of the U.S. population. There is an active and dedicated search for effective therapies to address this serious medical issue. The use of immunotherapy approaches for a number of diseases and conditions is continuously gaining momentum. Included in this is the use of CD34+ stem cells from a patients’ own blood (autologously derived) to treat cardiovascular disease. CD34+ is derived from bone marrow and other tissue types. However, CD34+ stems cells are more widely known for their hematopoietic origin.

Nearly 7 million people in the U.S. (about 2% of the total U.S. population) suffer some level of stroke-related brain damage and related health problems. Studies in animals suggest that cell-based therapies can improve post-stroke outcomes. To determine the safety of cell-therapy approaches in humans, researchers from Stanford University conducted a clinical trial to study the safety of a procedure to transplant donor stem cells in the brains of patients with chronic stroke. 

Researchers use bone marrow provided by HemaCare to help patients with critical limb ischemia.

Critical limb ischemia (CLI) is a condition caused by blocked arteries leading to low blood flow to the legs, feet, and other extremities. This causes severe pain, skin sores, gangrene, and can also lead to death. Amputation is often needed due to a lack of effective treatment options for CLI. The poor outcomes for patients with CLI have stimulated research efforts to find effective treatments such as autologous cell therapies. A new approach to treatment that is being investigated involves using cells from bone marrow aspirate supplied by HemaCare (bone marrow collected with a needle and syringe).